Premature ejaculation (PE) is a common sexual dysfunction taking place in men. In this, the ejaculation happens either shortly or before penetration during sexual intercourse, resulting in distress both the partners. No exact reason has been found till date for the problem, but premature ejaculation can be due to anxiety and personal problems that cause stress. An individual’s relationship with his partner can get affected due to such kind of problem. Data from the National Health and Social Life Survey have shown in the U.S. the occurrence of premature ejaculation in 21% of men between the ages of 18 to 59. The effective treatment options available for premature ejaculation are medications, psychological counseling, sexual techniques that delay ejaculation, or a combination of these.
The premature ejaculation treatment market can be segmented on the basis of drug class, treatment type and mode of administration. By drug class it can be divided into Phosphodiesterase type 5 (PDE5) inhibitors, Selective serotonin reuptake inhibitors (SSRIs) and Amide anesthetics. Recent studies have reported that the use of SSRIs in the treatment of premature ejaculation has delivered positive outcomes. SSRIs such as fluoxetine, paroxetine, sertraline, and clomipramine have been gaining importance among users. These drugs are used as off-label medications for treating premature ejaculation and are effective and efficient. On the basis of treatment types, it can be psychological, behavioral, pharmacologic interventions and others. Currently, most of the treatments are based on logical solutions (reducing sensory input), behavior modification therapies, or by observing the side effects of drugs, e.g. observing the serotonin reuptake inhibiting activity. On the basis of mode of administration, it can either be oral or topical.
The premature ejaculation treatment market is driven by several factors such as high use of off-label drugs and rise in unmet demands. At present, there is less number of recognized premature ejaculation drugs present in the market, thus offering a great opportunity to new players to entering the market. This unmet demand for the premature ejaculation drug is attracting several big pharmaceutical companies across the globe to take advantage by investing in R&D programs and develop new solutions. Recently, it has been observed that few key players in the pharmaceutical industry have moved further towards resolving the issue of lack of alternative treatment. They discovered that the injection of Botox into the bulbospongiosus, the exterior muscle in the penis that is responsible for erections, orgasms, and ejaculation, is a helpful technique. The market is also witnessing the introduction of several alternative treatments for premature ejaculation, which include herbal medications such as cinnamon bark, angelica, and clove. The main restraint of the market is the lack of awareness in the developing countries towards available advanced treatment options and ignorance. Many people consider it as a disease but it is a just a problem with solutions available in the market. As such kind of problems leads to a lot of personal distress and thus, lowering the self-esteem of the individual, so in most of the cases, people hide it rather than consulting a doctor on right time. Trending in the segment is the increasing online retail sales of drugs. Online retailing is considered as the fastest channel of distribution. The acceptance of online retailing can be recognized due to factors such as the quick delivery services, availability of a broad range of products, and highly competitive pricing.
Based on geography, the global premature ejaculation market has been divided into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is the largest revenue-generating region in the market followed by Europe. A major reason for the market growth in North America is a substantial rise in the number of premature ejaculation patients due to psychological factors such as stress resulting from changing lifestyle and workload. Factors such as the increase in awareness among public and health professionals of the signs and symptoms of premature ejaculation and the need to treat the condition for a satisfactory sex life have boosted the growth of the market in this region. The Asia Pacific market is growing rapidly due to rise in the number of cases reported for premature ejaculation. Also, increasing disposable income in East Asian countries is opening new doors for better treatment options. Middle East & Africa is expected to grow at a fast pace in the premature ejaculation market during the forecast period due to rise in the government initiative towards increasing awareness in the region. Latin America is expected to show steady growth in the premature ejaculation market due to unavailability of proper treatment options.
The premature ejaculation treatment market is oligopolistic in nature which is being dominated by key international vendors like Absorption Pharmaceuticals, Allergan, Innovus and Plethora. Other prominent vendors are Dong-A Pharmaceutical, Bayer, Emcure, Eli Lilly, Futura Medical, NeuroHealing Pharmaceuticals, GlaxoSmithKline, and Pfizer.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.